文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

不同SARS-CoV-2变异株疫情期间欧洲经验中心体外膜氧合治疗COVID-19的结局比较(ECMO-SURGES):一项国际多中心回顾性队列研究

Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study.
PubMed 文献 · Lancet Respir Med · 2023-01-11
一句话结论在21个欧洲经验中心接受ECMO的COVID-19相关ARDS患者90天死亡率为42%,校正后delta变异株死亡风险最高,野生型为参照。

该国际多中心回顾性队列纳入2020年1月1日至2021年9月30日8个欧洲国家21个经验ECMO中心连续收治的1345例实验室确诊SARS-CoV-2感染并因ARDS接受ECMO的成人患者,按变异株(野生型、alpha、delta、其他)和疫情半年度分组。总体90天死亡率为42%(569/1345),野生型43%(297/686)、alpha 39%(152/391)、delta 40%(78/195)、其他变异株(主要为beta和gamma)58%(42/73);2020年第二半年度野生型仍流行时死亡率为50%,较其他半年度(40%)高10%。独立死亡预测因素包括年龄、免疫抑制状态、ICU入住至插管时间较长、需要肾脏替代治疗,以及ECMO前更高的SOFA血流动力学分量表评分、动脉血二氧化碳分压和乳酸浓度;校正这些变量后,delta变异株死亡风险显著高于其他变异株(野生型为参照)。作者认为应提高人群疫苗接种率并更新ECMO选择标准,并将资源集中于经验中心。

要点

  • 总体90天死亡率42%(569/1345);野生型43%(297/686)、alpha 39%(152/391)、delta 40%(78/195)、其他变异株58%(42/73)。
  • 2020年第二半年度(野生型仍流行)死亡率50%,较其他半年度(40%)高10%。
  • 独立死亡预测因素:年龄、免疫抑制、ICU入住至插管时间较长、需要肾脏替代治疗、ECMO前SOFA血流动力学分量表评分更高、PaCO2更高、乳酸更高。
  • 校正上述变量后,delta变异株死亡风险显著高于其他变异株,野生型为参照。
  • 作者认为应提高人群疫苗接种率并更新ECMO选择标准,以应对未来可能出现的高毒力变异株。

适用人群与场景

  • 8个欧洲国家(奥地利、比利时、英格兰、法国、德国、意大利、葡萄牙、西班牙)21个经验ECMO中心连续收治的成人患者,实验室确诊SARS-CoV-2感染并因ARDS接受ECMO,时间2020年1月1日至2021年9月30日。
  • 按SARS-CoV-2变异株(野生型、alpha、delta或其他)及疫情半年度(2020年第一半年度1月1日至6月30日、第二半年度7月1日至12月31日;2021年第一半年度1月1日至6月30日、第二半年度7月1日至9月30日)分组。

研究设计与关键结果

  • 研究类型:国际多中心回顾性队列研究,纳入1345例因COVID-19相关ARDS接受ECMO的成人患者。
  • 主要终点为ECMO启动后90天死亡率,随访至2021年12月30日;总体90天死亡率42%(569/1345)。
  • 90天死亡率:野生型43%(297/686)、alpha变异株39%(152/391)、delta变异株40%(78/195)、其他变异株(主要为beta和gamma)58%(42/73)。
  • 2020年第二半年度(野生型仍流行)死亡率50%,较其他半年度(40%)高10%。
  • 独立死亡预测因素:年龄、免疫抑制状态、ICU入住至插管时间较长、需要肾脏替代治疗、ECMO前SOFA血流动力学分量表评分更高、动脉血二氧化碳分压更高、乳酸浓度更高。
  • 校正上述变量后,delta变异株死亡风险显著高于其他变异株,野生型为参照。
  • 不同变异株组患者特征与治疗相似,但delta变异株组中位年龄更小、高血压和糖尿病更少。

证据类型、等级与局限

  • 证据类型:国际多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,delta变异株相关毒力更高和结局更差可能与感染者病毒载量更高和炎症反应综合征增强有关,这强化了提高人群疫苗接种率的必要性,并需更新ECMO选择标准,以应对未来可能出现的新高毒力SARS-CoV-2变异株。
  • 作者认为,本组死亡率明显低于其他大型多中心COVID-19 ECMO系列,突显了将资源集中于经验中心的必要性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: To inform future research and practice, we aimed to investigate the outcomes of patients who received extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome (ARDS) due to different variants of SARS-CoV-2.

METHODS: This retrospective study included consecutive adult patients with laboratory-confirmed SARS-CoV-2 infection who received ECMO for ARDS in 21 experienced ECMO centres in eight European countries (Austria, Belgium, England, France, Germany, Italy, Portugal, and Spain) between Jan 1, 2020, and Sept 30, 2021. We collected data on patient characteristics, clinical status, and management before and after the initiation of ECMO. Participants were grouped according to SARS-CoV-2 variant (wild type, alpha, delta, or other) and period of the pandemic (first [Jan 1-June 30] and second [July 1-Dec 31] semesters of 2020, and first [Jan 1-June 30] and second [July 1-Sept 30] semesters of 2021). Descriptive statistics and Kaplan-Meier survival curves were used to analyse evolving characteristics, management, and patient outcomes over the first 2 years of the pandemic, and independent risk factors of mortality were determined using multivariable Cox regression models. The primary outcome was mortality 90 days after the initiation of ECMO, with follow-up to Dec 30, 2021.

FINDINGS: ECMO was initiated in 1345 patients. Patient characteristics and management were similar for the groups of patients infected with different variants, except that those with the delta variant had a younger median age and less hypertension and diabetes. 90-day mortality was 42% (569 of 1345 patients died) overall, and 43% (297/686) in patients infected with wild-type SARS-CoV-2, 39% (152/391) in those with the alpha variant, 40% (78/195) in those with the delta variant, and 58% (42/73) in patients infected with other variants (mainly beta and gamma). Mortality was 10% higher (50%) in the second semester of 2020, when the wild-type variant was still prevailing, than in other semesters (40%). Independent predictors of mortality were age, immunocompromised status, a longer time from intensive care unit admission to intubation, need for renal replacement therapy, and higher Sequential Organ Failure Assessment haemodynamic component score, partial pressure of arterial carbon dioxide, and lactate concentration before ECMO. After adjusting for these variables, mortality was significantly higher with the delta variant than with the other variants, the wild-type strain being the reference.

INTERPRETATION: Although crude mortality did not differ between variants, adjusted risk of death was highest for patients treated with ECMO infected with the delta variant of SARS-CoV-2. The higher virulence and poorer outcomes associated with the delta strain might relate to higher viral load and increased inflammatory response syndrome in infected patients, reinforcing the need for a higher rate of vaccination in the population and updated selection criteria for ECMO, should a new and highly virulent strain of SARS-CoV-2 emerge in the future. Mortality was noticeably lower than in other large, multicentre series of patients who received ECMO for COVID-19, highlighting the need to concentrate resources at experienced centres.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Schmidt M, Hajage D, Landoll M, et al. Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study. Lancet Respir Med. 2023. PMID: 36640786. doi:10.1016/S2213-2600(22)00438-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。